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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
14.05.2020 Pulmonary 
arterial 
thrombosis in 
COVID-19 with 
fatal outcome: 
results from a 
prospective 
single-center, 
clinicopathologic 
case series 
Annals of 
Internal 
Medicine | 
Article 
 COVID-19 predominantly 
involved the lungs in 11 
deceased patients with 
COVID-19 in this small 
prospective autopsy study, 
causing diffuse alveolar 
damage (DAD) and acute 
respiratory insufficiency 
 Death may be caused by the 
thrombosis observed in 
segmental and subsegmental 
pulmonary arterial vessels 
despite the use of 
prophylactic anticoagulation 
13.05.2020 Multiorgan and 
renal tropism of 
SARS-CoV-2 
NEJM | 
Correspondence 
 In this autopsy series of 27 
patients, authors found 
SARS-CoV-2 had a 
organotropism beyond the 
respiratory tract, including the 
kidneys, heart, liver and brain 
 Authors speculate that 
tropism influences the course 
of COVID-19 disease and 
2 
possibly aggravates pre-
existing conditions 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
11.05.2020 Prevalence of 
COVID-19 
symptoms, 
risk factors, 
and health 
behaviours in 
host and 
refugee 
communities 
in Cox’s 
Bazar: a 
representative 
panel study 
Bulletin of 
WHO | Article 
 A phone-based survey was 
administered to a sample of 909 
households in Cox’s Bazar drawn 
from a household panel 
representative of Rohingya 
refugees and the host population 
 24.6% of camp residents and 
13.4% of those in host 
communities reported at least one 
common symptom of COVID-19 
 Among those seeking treatment 
42.3% in camps and 69.6% in 
host communities did so at a 
pharmacy 
 76.7% of those in camps and 
52.2% of those in the host 
community had attended a 
communal prayer in the previous 
week and another 47.4% in 
camps and 34.4% in the host 
community had attended a non-
religious social gathering 
 COVID-19 symptoms are highly 
prevalent in Cox’s Bazar, 
especially in refugee camps. 
Religious and social events 
threaten efforts to reduce 
transmission. Pharmacies and 
religious leaders could help 
disseminate COVID-19 
messaging 
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Testing 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
13.05.2020 Towards 
effective 
diagnostic 
assays for 
COVID-19: 
A review 
J Clin Pathol. | 
Review 
 Summary of evidence for diagnoses 
of cases and to aid laboratories and 
healthcare workers to select the best 
assays and procedures 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary 
14.04.2020 Proteomics of 
SARS-CoV-2-
infected host cells 
reveals therapy 
targets 
Nature | 
Article 
 This study identifies the host 
cell pathways modulated by 
SARS-CoV-2 infection and 
show that inhibition of these 
pathways prevent viral 
replication in human cells 
14.05.2020 Hydroxychloroquine 
in patients with 
mainly mild to 
moderate 
coronavirus 
disease 2019: open 
label, randomised 
controlled trial 
BMJ | Article 
 Hospitalised adult patients 
with mainly mild to moderate 
persistent COVID-19 who 
received hydroxychloroquine 
plus standard of care did not 
clear the virus more quickly 
than those receiving standard 
of care alone in this 
multicentre, open label 
randomised controlled trial in 
China, 11 to 29 February 
2020 
 Adverse events were high in 
hydroxychloroquine 
recipients than in non-
recipients 
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Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
15.05.2020 Health inequity during the COVID-
19 pandemic: a cry for ethical 
global leadership 
The Lancet | 
Correspondence 
David Chiriboga 
Juan Garay 
Paulo Buss 
Rocio Saenz 
Madrigal 
Laetitia 
Charmaine 
Rispel 
14.05.2020 Global coordination on cross-
border travel and trade measures 
crucial to COVID-19 response 
The Lancet | Comment Kelley Lee 
Catherine Z 
Worsnop 
Karen A Grepin 
Adam Kamradt-
Scott 
14.05.2020 An appeal for practical social 
justice in the COVID-19 global 
response in low-income and 
middle-income countries 
The Lancet Global 
Health | Comment 
Maureen Kelley 
Rashida A 
Ferrand 
Kui Muraya 
Simukai Chigudu 
Sassy Molyneus 
Madhukar Pai et 
al.  
14.05.2020 Leveraging Africa’s preparedness 
towards the next phase of the 
COVID-19 pandemic 
The Lancet Global 
Health | Comment 
Madikay 
Senghore 
Merveille K Savi 
Benedicte 
Gnangnon 
5 
William P 
Hanage 
Iruka N Okeke 
14.05.2020 COVID-19 response in the Middle 
East and north Africa: challenges 
and paths forward 
The Lancet Global 
Health | Comment 
Mohammad 
Karamouzian 
Navid Madani 
14.05.2020 Dozens of coronavirus drugs are in 
development – what happens 
next? 
Nature | News Heidi Ledford 
14.05.2020 Machine learning can help get 
COVID-19 aid to those who need it 
most 
Nature | World View Joshua 
Blumenstock 
13.05.2020 Health in a time of COVID-19 – 
how and where do we start 
strengthening health systems? 
Health Policy and 
Planning | Blog 
Fiona Samuels 
Ana B. Amaya 
Dina Balabanova 
13.05.2020 How COVID-19 is changing the 
world: a statistical perspective 
from international agencies  
World Bank | Blog Haishan Fu 
12.05.20 Impact of international travel 
dynamics on domestic spread of 
2019-nCoV in India: origin-based 
risk assessment in importation of 
infected travellers 
Globalization and 
Health | Commentary 
Sachin S. 
Gunthe 
Satya S. Patra  
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Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
13.05.2020 COVID-19 and the 
need for action on 
mental health 
UN | 
Policy 
Brief 
 Rapid implementation of three 
recommended actions will be 
essential to ensure people and 
societies are better protected 
from the mental health impact of 
COVID-19 
 A study in Ethiopia in April 2020 
reported a 3-fold increase in the 
prevalence of symptoms of 
depression compared to 
estimates from before the 
epidemic 
 April 2020 Considerations and 
principles for 
shielding people at 
high risk of severe 
outcomes from 
COVID-19 
 SSHAP | 
Brief 
 Provides an overview of 
proposed approaches to 
shielding individuals at high risk 
of severe disease or death from 
COVID-19 in LMICs and 
considers feasibility, challenges 
and ways to mitigate them 
 Decisions on shielding must 
consider local socio-economic 
context, involve local actors and 
adapt in response to new 
evidence about the approach’s 
effectiveness, characteristics of 
COVID-19 and outbreak 
trajectories 
Dashboards & Trackers 
Cases & 
deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living 
evidence 
& policy 
maps 
Current 
research 
including trials 
  Diagnosti
cs 
  Treatment
s 
  Vaccin
es 
WHO 
sitreps 
WHO 
Africa 
Ghana COVID-
NMA 
WHO   FIND 
SARS-
CoV-2 Test 
Tracker 
  Global 
COVID-19 
Clinical 
Trial 
Tracker 
  CEPI 
7 
WHO 
dashboard 
African 
Argumen
ts 
Indonesi
a 
EPPI 
Centre 
WHO 
International 
Clinical Trials 
Registry 
Platform 
(ICTRP) 
 FIND 
SARS-
CoV-2 
Diagnostic
s: 
performanc
e data 
  US NIH 
registered 
clinical 
trials 
Vaccine 
Centre 
LSHTM 
Johns 
Hopkins 
University 
Europea
n CDC 
Nigeria 
CDC 
Norwegian 
Institute of 
Public 
Health 
Cytel  Serology-
based 
tests for 
COVID-19 
  Solidarity 
trial 
 COVID-
19 
Oxford 
Vaccine 
Trial 
WEF 
  Sierra 
Leone 
 Oxford 
C19 
Governme
nt 
Response 
Tracker 
(OxCGRT) 
US NIH  Our World 
in Data: 
C19 
Testing 
  COVID-
19 
Therapeuti
cs 
Accelerator 
  
Our World 
in Data 
  Singapor
e 
 Our World 
in Data: 
C19 Policy 
responses 
COVID-
evidence 
      
Global 
5050 
  UK   Cochrane       
CEBM, 
University 
of Oxford 
  US   Clinicaltrials.g
ov 
      
Humanitari
an Data 
Exchange 
       UKCDR       
Information 
is Beautiful 
              
LSHTM               
8 
HealthMap 
(cases) 
              
The 
Commons 
Project 
              
C19 Resource Hubs 
Global  Region
al & 
Country 
Academi
c journals 
& 
Publisher
s 
Global Health 
Institutes/Centres/Funders/O
ther 
Health 
Topics 
  Social 
Sciences 
WHO COVID-
19 pandemic  
Africa 
CDC 
The 
Lancet 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicatio
n 
African 
Union 
NEJM LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Elsevier ICL MRC Centre for Global 
Infectious Disease Analysis  
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPoll
: SSA 
BMJ ODI SLH: 
Handwashi
ng in low 
resource 
settings 
  Coregrou
p IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell 
Press 
Johns Hopkins University 
 
  Rings 
HSG 
Resyst 
Reach 
Wellcome 
UN African 
Academ
y of 
Cochran
e 
Center for Global 
Development 
    Social 
Developme
nt Direct 
9 
Science
s 
resource
s 
C19 blog 
series 
UN Women Africa 
Evidenc
e 
Network 
PLoS CMMID Repository     
UNOCHA   Annals of 
Internal 
Medicine 
Norwegian Institute of Public 
Health 
    
UNHCR    Wiley 
Health 
Economi
cs 
Oxford Centre for Evidence-
based Medicine 
    
UNICEF    Pre-
prints 
medRxiv 
and 
bioRxiv 
 HEART     
UNESCO   SAGE 
journals 
 UKRI     
UN WFP   JAMA  Evidence Aid     
GOARN    Bulletin 
of the 
WHO 
 NIH     
EPI-WIN           
World Bank           
Our World in 
Data 
          
COVID-19 
Narratives by 
          
10 
David 
Nabarro 
Reliefweb           
Humanitarian 
OpenStreetM
ap Team 
          
Global 
Partnership 
for 
Sustainable 
Development 
Data 
          
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global Impact 
Study 
    
  
Online learning & events 
Date Title/URL Online 
learning/event 
Duration Lead 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, Modelling 
and Policy 
Online 
learning 
2 weeks | 2 
hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11 
11.5.2020 COVID-19 Contact 
Tracing course 
Online 
learning 
5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays at 
1700 CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
Event 1h 20 Gresham College 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
prevention, response 
and control 
Online 
learning 
3 hours WHO 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online 
learning 
Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel Coronavirus 
Online 
learning 
3 weeks | 4 
hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
COVID-19 
Diagnostics and 
Testing 
Online 
learning 
3 weeks | 3 
hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
12 
version will 
commence 
early June 
2020 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online 
learning 
5 weeks | 1 
hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online 
learning 
Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
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About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
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